Proteolytic shedding of CD46 from human hepatocytes indicates liver stress
2024

CD46 Shedding as a Biomarker for Liver Stress

Sample size: 200 publication 10 minutes Evidence: high

Author Information

Author(s): Paul Kupke, Jordi Yang Zhou, Gunther Glehr, Paloma Riquelme, Lena Scheibert, Akinbami Adenugba, Hans J. Schlitt, Edward K. Geissler, Jens M. Werner, James A. Hutchinson

Primary Institution: University Hospital Regensburg

Hypothesis

Can soluble CD46 (sCD46) serve as a sensitive biomarker for early liver stress in various liver diseases?

Conclusion

sCD46 is a promising biomarker for detecting early liver diseases and monitoring therapeutic responses.

Supporting Evidence

  • sCD46 levels were significantly higher in steatotic patients compared to non-steatotic patients.
  • Prostaglandin E2 treatment increased sCD46 release in fat-loaded HepaRG cells.
  • Hepatitis E virus infection led to increased sCD46 release from HepaRG cells.
  • Drug exposure to certain cytostatic compounds increased sCD46 levels in HepaRG cell supernatants.

Takeaway

Scientists found that a protein called sCD46 can help doctors see if the liver is stressed or sick, even before other tests show problems.

Methodology

The study developed and validated an ELISA to measure sCD46 levels in human plasma and serum, analyzing its release under various stress conditions.

Potential Biases

Potential bias due to the study being conducted at a single center.

Limitations

The kinetics of sCD46 release and its degradation were not assessed, which is important for its interpretation as a clinical biomarker.

Participant Demographics

Included 158 patients undergoing liver tumor resection and 42 patients with chronic hepatitis C.

Statistical Information

P-Value

p<0.05

Confidence Interval

95% CI [93.5, 100]

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1016/j.heliyon.2024.e40841

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication